Posted by Sigismund on August 8, 2009, at 15:25:08
In reply to Re: sleep on Agomelatine, posted by Hundredwaters on August 8, 2009, at 2:41:30
Here is what googletranslate does to Russian....
I have no idea if it is meaningful. It is certainly very funny.
Afobazol - anksiolitik selective, having no analogues in the world. It differs from benzodiazepinovyh tranquilizers lack of sedation, miorelaksatsii, memory disorders, and dependence syndrome cancel. Afobazol possesses neuroprotective properties, which makes it promising for use in a wide range of psychiatric and neurological diseases.
NCI under contract aims to create injection dosage form afobazola, the development of scientific and technical documentation, the study of the spectrum combined anxiolytic and neyroprotektornoy activity in various models, the study of molecular mechanisms for the implementation of these effects
A study of pharmacological properties neyroprotektornyh afobazola in experiments in vitro and in vivo using models of ischemic and hemorrhagic stroke. Are mezhlineynye differences in the change in response to the stress levels of brain neurotrophic factor BDNF in animals with different phenotype emotional stress reactions. We show that afobazol (5 mg / kg) prevents the reduction of BDNF, and its effect is more pronounced in Animals with genetically determined response of expressed fear. In this series of experiments confirmed hypotheses about the combined anxiolytic and neyroprotektornyh properties afobazola. Neyroprotektorny effect afobazola proven models of oxidative stress and toxicity glumatnoy in culture cells.Neyroprotektorny effect afobazola confirmed in models of ischemic and hemorrhagic stroke in a wide range of doses. Optimal regimes of introduction, including the effectiveness during the first application within the therapeutic window.
It is shown that afobazol causes a significant increase in cerebral blood flow in rats that had transient global cerebral ischemia, and increases survival of animals under conditions of ischemia caused by occlusion of common carotid arteries.
When studying the metabolism found that after oral introduction afobazol exposed to effects of «first-pass through the liver». Are metabolites afobazola.In pharmaceutical research developed injection form afobazola, drafted FAK in substance and «Afobazola Solution for injection 1%».
A full range of preclinical safety studies injection dosage form afobazola (1% solution).
prospects for the use of medication for acute violations of the cerebral circulation and in the recovery period to reduce the expression kupirovaniya neurologic symptoms and anxiety disorder. The directions of the development of a protocol of clinical study in patients with ischemic disorders of cerebral circulation 1% solution afobazola - 1 ml, in ampoules, as anksiolitika with neyroprotektornymi properties. Continue to develop promising to introduce afobazola in practice in a new dosage form as a means of treating stroke and neurodegenerative diseases.
Thus, from a contract R & D results confirmed that the developed drugs are able to not only address the symptoms of anxiety disorder, and had a key effect on the neurochemical and molecular mechanisms of emotional-stress reaction. These drugs do not cause side effects that contribute to reducing or impairing the performance or purposeful activity, and may be used in the pharmacology of human health and in emergency medicine.Development and introduction of drugs will increase the efficiency of pharmacotherapy of various pathological conditions, including neurodegenerative diseases, which are based on stressors disorders, including their vnegospitalnom treatment that will also be an important contribution to the prevention of common diseases, severe somatic and mental pathology.
poster:Sigismund
thread:910561
URL: http://www.dr-bob.org/babble/20090801/msgs/910939.html